Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
July 2022
-
Featured NewsFrom the Heart
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic…
-
Key ReleaseNovartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidanceAd hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…
-
Key Release
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im zweiten Quartal um +5% kWk1 (–1% USD) Innovative Medicines (IM) steigerte den Umsatz um +5% kWk (–1% USD); starke Performance der… -
Key Release
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1 (-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec… -
Featured NewsNovartis Financial Results – Q2 2022
Novartis announced the company’s financial results for the second quarter and first half of 2022.
June 2022
-
Media ReleaseNew Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapyFirst-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal…
-
Media ReleaseNovartis resumes production and delivery of radioligand therapy medicines ahead of scheduleProduction and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy…
-
Media ReleaseNew Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)New data from the Phase 3 ASCLEPIOS I/II trials and ALITHIOS open-label extension show that after four years nearly 8 out of 10 of people with relapsing multiple sclerosis (RMS) treated continuously…
-
Media ReleaseCosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditionsApprovals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with…
-
Media ReleaseNovartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemiaWith unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at…
-
Renewing our commitment to neglected tropical disease and malaria elimination
Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.
Pagination
- ‹ Previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- …
- 150
- › Next page